Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response variability to P2Y12 receptor inhibitors: expectations and reality.

JACC. Cardiovascular interventions - 1 Nov 2013

Siller-Matula Jolanta M, Trenk Dietmar, Schrör Karsten, Gawaz Meinrad, Kristensen Steen D, Storey Robert F, Huber Kurt

Abstract excerpt

P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the secondary prevention of thrombotic events in vascular diseases. Within the past few years, several pharmacological, genetic, and clinical limitations of the second-generation thienopyridine clopidogrel have raised major concerns. High on-treatment platelet reactivity, which is common in clopidogrel-treated patients, and its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Fibrinolytic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemorrhage

Share to Platelet Aggregation

Share to Platelet Aggregation Inhibitors

Share to Platelet Function Tests

Share to Purinergic P2Y Receptor Antagonists

Share to Receptors, Purinergic P2Y12

Source

Identifiers

PMID: 24262612
DOI: 10.1016/j.jcin.2013.06.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response variability to P2Y12 receptor inhibitors: expectations and reality.PMID 24262612Read ↗

High platelet reactivity and clinical outcome - fact and fiction.Semantic proximity Read ↗

P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.Semantic proximity Read ↗

Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests.Semantic proximity Read ↗

Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.Semantic proximity Read ↗

Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel.Semantic proximity Read ↗

Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.Semantic proximity Read ↗

Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention.Semantic proximity Read ↗

High on-clopidogrel platelet reactivity: genotyping can help to optimize antiplatelet treatment.Semantic proximity Read ↗

Pharmacogenetics of Antiplatelet Therapy.Semantic proximity Read ↗

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Semantic proximity Read ↗

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.Semantic proximity Read ↗

Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.